Pfizer Inc. reported financial results for the third quarter of 2025 and reaffirmed its 2025 Revenue guidance(1) while raising and narrowing guidance for Adjusted(2) diluted EPS. EXECUTIVE COMMENTARY ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback